Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1,643 SEK | +1.08% | -1.76% | +21.39% |
02/06 | Astra's Enhertu breast cancer trial shows 'unprecedented' results | RE |
02/06 | Astra's Enhertu delays breast cancer in patients with low HER2 levels | RE |
Strengths
- Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
- The group's activity appears highly profitable thanks to its outperforming net margins.
- Analysts have consistently raised their revenue expectations for the company, which provides good prospects for the current and next years in terms of revenue growth.
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
- The average price target of analysts who are interested in the stock has been strongly revised upwards over the last four months.
Weaknesses
- The firm trades with high earnings multiples: 21.51 times its 2024 earnings per share.
- The company's "enterprise value to sales" ratio is among the highest in the world.
- The company appears highly valued given the size of its balance sheet.
- Over the past twelve months, analysts' consensus has been significantly revised downwards.
- Financial statements have repeatedly disappointed market stakeholders. Most often, they were below expectations.
Ratings chart - Surperformance
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+21.39% | 24TCr | - | ||
+40.73% | 74TCr | C+ | ||
+32.83% | 60TCr | B | ||
-6.30% | 35TCr | C+ | ||
+15.15% | 32TCr | B- | ||
+4.05% | 28TCr | C+ | ||
+9.78% | 21TCr | B- | ||
-5.52% | 21TCr | A+ | ||
+6.17% | 16TCr | C+ | ||
-0.45% | 16TCr | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- AZN Stock
- AZN Stock
- Ratings AstraZeneca PLC